ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Cambrex will spend $9 million to expand its small-molecule active pharmaceutical ingredient (API) facility in Karlskoga, Sweden. The investment will add 28 m3 of capacity at the site, roughly a 10% increase, according to Cambrex. “This investment is in response to an increase in demand for larger-scale, multipurpose manufacturing capabilities, says Bjarne Sandberg, managing director of Cambrex Karlskoga. Cambrex recently invested $50 million in its Charles City, Iowa, API facility and said it would spend $20 million on further expansion by year-end.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X